Processa Pharmaceuticals Inc expected to post a loss of 19  cents a share - Earnings Preview

Processa Pharmaceuticals

28/03/2022 21:39

* Processa Pharmaceuticals Inc  PCSA.OQ   PCSA.O  is
expected
to show no change in quarterly revenue when it reports 
results on March 30. 
    * ​Refinitiv's mean analyst estimate for Processa
Pharmaceuticals
Inc is for a loss of 19 cents per share. For the same quarter
last year, the company reported a loss of $1.69 per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Processa
Pharmaceuticals Inc is $17​, above​ its last closing price
of $3.22. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.18       -0.18      -0.19     Missed  -3.6
 Jun. 30 2021  -0.14       -0.14      -0.20     Missed  -39.5
 Mar. 31 2021  -0.10       -0.10      -0.14     Missed  -33.3​
 Dec. 31 2020  -0.16       -0.35      -1.69     Missed  -376.1
 ​​Sep.        -0.16       -0.16      -0.55     Missed  -243.7
 30 2020                                                
                                                        ​
 This summary was machine generated March 28 at 20:39 GMT.  All
figures in US dollars  unless otherwise stated